news

CUPERTINO, Calif., Sept. 25, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3 at 1:40 p.m. Eastern Time.  The conference is being held at the InterContinental New York Barclay hotel in New York City.  Institutional […]

– ORADUR®-Methylphenidate ER now called Methydur Sustained Release Capsules in Taiwan – Developed by Orient Pharma under a license to the ORADUR® technology from DURECT CUPERTINO, Calif., Sept. 18, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd., its licensee for certain Asian and South Pacific countries, has informed DURECT that

Milestone payment triggered by NDA approval of PERSERIS™ (risperidone) CUPERTINO, Calif., Aug. 30, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has received a $5 million milestone payment from Indivior PLC (LON: INDV), triggered by Indivior’s approval of the New Drug Application (NDA) for PERSERIS™ (risperidone) in July 2018.  On September 26,

CUPERTINO, Calif., Aug. 27, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., on Thursday, September 6 at 9:10 a.m. Eastern Time.  The conference is being held at the St.

CUPERTINO, Calif., Aug. 6, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics’ New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII, which concluded that “The data

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Aug. 1, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2018 and provided a corporate update.   Total revenues were $3.4 million and net loss was $7.0 million for the three months

Approval triggers $5 million milestone payment to DURECT and future earn-out payments based on U.S. net sales CUPERTINO, Calif., July 30, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for PERSERIS™ (risperidone), which

CUPERTINO, Calif., July 24, 2018 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, August 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast

CUPERTINO, Calif., June 26, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14 to 3 against the approval of REMOXY® ER (oxycodone extended-release capsules) for

CUPERTINO, Calif., May 9, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the “Amendment”) to the development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), regarding POSIMIR® (SABER®-bupivacaine) in the United States.   DURECT received an upfront payment from Sandoz of $20 million at the